Guideline Page and Request

Internal request
Consider the addition of a footnote indicating that an FDA-approved biosimilar is an appropriate substitute for rituximab, adalimumab, and etanercept.

Panel Discussion/References

The panel consensus was to include a footnote for biosimilars:
- An FDA-approved biosimilar is an appropriate substitute for rituximab.
- An FDA-approved biosimilar is an appropriate substitute for adalimumab.
- An FDA-approved biosimilar is an appropriate substitute for etanercept.

Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>